Table 2.
Multivariate analysis of impact factors for ypN+ in the whole population.
| Factors | OR | 95% CI | p-value |
|---|---|---|---|
| Clinical stage | <0.001 | ||
| cT1-2N0 | 1 | ||
| cT1-2N1 | 5.48 | 3.77–7.97 | <0.001 |
| LABC | 10.90 | 7.12–16.70 | <0.001 |
| ER | 0.092 | ||
| Negative | 1 | ||
| Positive | 1.32 | 0.96–1.82 | |
| PR | 0.617 | ||
| Negative | 1 | ||
| Positive | 0.89 | 0.58–1.39 | |
| HER2 | 0.270 | ||
| Negative | 1 | ||
| Positive | 0.81 | 0.56–1.17 | |
| Molecular subtypes | 0.326 | ||
| Luminal-A like | 1 | ||
| Luminal-B (HER2–) | 1.19 | 0.64–2.25 | 0.583 |
| Luminal-B (HER2+) | 0.82 | 0.41–1.64 | 0.579 |
| HER2-amplified | 0.87 | 0.42–1.81 | 0.703 |
| TNBC | 0.81 | 0.40–1.63 | 0.552 |
| Grade | 0.045 | ||
| I–II | 1 | ||
| III | 1.39 | 1.01–1.92 | |
| NAC regimens | 0.232 | ||
| A contained | 1 | ||
| T contained | 0.81 | 0.44–1.48 | 0.491 |
| A+T combination | 1.17 | 0.72–1.89 | 0.531 |
| Neoadjuvant targeted therapy | <0.001 | ||
| No | 1 | ||
| Yes | 0.40 | 0.27–0.59 | |
| Breast pCR | <0.001 | ||
| No | 1 | ||
| Yes | 0.14 | 0.09–0.21 |
A, anthracyclines; CI, confidence interval; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; LABC, locally advanced breast cancer; NAC, neoadjuvant chemotherapy; OR, odds ratio; pCR, pathological complete remission; PR, progesterone receptor; T, taxanes; TNBC, triple negative breast cancer.